Drug profile · INN
halcinonide
HALOG-E
halcinonide (HALOG-E) is a glucocorticoid receptor agonist. Route of administration: topical. Current US regulatory status: approved.
Drug details — halcinonide
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 20
- Programs
- 1
- Data quality
- 0.84
Quick answer
halcinonide (HALOG-E) is a glucocorticoid receptor agonist. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12377068
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
granted -
US 12357650
Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation
granted -
US 12252714
Halogenation of complex organic compounds
granted -
US 12138276
Halogenated psilocybin derivatives and methods of using
granted -
US 12133840
Halogenated xanthene composition and method for treating hematologic cancers
granted -
US 11998557
Halogenated psilocybin derivatives and methods of using
granted -
US 11974980
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
granted -
US 11975106
Uses of halogenated xanthenes in oncology and virology
granted -
US 11938182
Halogenated xanthenes as vaccine adjuvants
granted -
US 11696898
Halogenated ether compounds and methods of inducing anesthesia
granted -
US 11692176
Halogenation of complex organic compounds
granted -
US 11654157
Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation
granted -
US 11419844
Halogenated xanthene composition and method for treating hematologic cancers
granted -
US 11351276
Radiopharmaceutical compositions of radioactive halogenated benzylguanidine
granted -
US 11254662
2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof
granted -
US 11058664
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
granted -
US 11008553
Halogenation of complex organic compounds
granted -
US 10633351
Halogenated compound and axially chiral isomer thereof
granted -
US 9572881
Halogenated compounds for photodynamic therapy
granted -
US 9296774
Halogenated dideoxy sugar derivates, preparation method and application thereof
granted
Frequently asked questions
What is halcinonide?
halcinonide (HALOG-E) is a glucocorticoid receptor agonist. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for halcinonide?
HALOG-E is a marketed brand name for halcinonide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of halcinonide?
halcinonide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.